2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
The DiSMS platform enables accurate, cost-accessible plasma P-tau217 quantification for AD screening, meeting consensus guidelines (≥90%), and the limited P-tau217 performance for differentiating AD from FTD highlights the need for integration with complementary biomarkers or clinical assessments.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
